Latest "Placebo Hepatitis Virus Infection" News Stories

04:33 EST 25th February 2017 | BioPortfolio

Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.

More Information about Placebo Hepatitis Virus Infection on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.

Showing "Placebo Hepatitis Virus Infection" News Articles 1–25 of 7,700+

Extremely Relevant

Warning: Reactivation of Hepatitis B Virus Coinfection During Treatment of Chronic Hepatitis C Virus Infection

SYNOPSIS: Prior to initiation of hepatitis C virus treatment with direct-acting antivirals, patients should be screened for hepatitis B virus coinfection. Those who are hepatitis B virus-infected should receive ongoing monitoring for flares and reactivation of hepatitis B.

HCV Drug Warning

The FDA will require boxed warnings on labels for certain direct-acting antiviral medications used to treat hepatitis C virus (HCV) infection following reports that the drugs reactivated hepatitis B virus (HBV) infection.

Hepatitis C Infection for Primary Care Providers

Hepatitis C virus (HCV) can cause both acute and chronic hepatitis. Most people are asymptomatic, but for the majority of patients who become infected with hepatitis C, it becomes a long-term, chronic infection. The best way to prevent hepatitis C is by avoiding behaviors that can spread the disease, especially injection drug use, as there is no vaccine for HCV. With the forefront of direct-acting...

FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C

[10-04-2016] The U.S. Food and Drug Administration (FDA) is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for hepatitis C virus.

[Comment] Eliminating hepatitis B virus as a global health threat

In The Lancet Infectious Diseases, Shevanthi Nayagam and colleagues1 report a modelling study on the effectiveness of different interventions on the incidence and mortality rate of chronic hepatitis B virus (HBV) infection. To appreciate the implications of this report, we need to understand the context. Chronic viral hepatitis is the seventh leading cause of death worldwide.2 Chronic HBV infectio...

FDA approves Gilead’s Vemlidy to treat chronic hepatitis B virus infection

The US Food and Drug Administration (FDA) has approved Gilead Sciences' Vemlidy (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease.

Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating

Audience: Infectious Disease, Gastroenterology, Patient [Posted 10/04/2016] ISSUE: The FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and...

BRIEF-Assembly Biosciences starts Phase 1 program of treatment for Hepatitis B virus infection

* Initiates phase 1 clinical program of abi-h0731 for treatment of chronic hepatitis b virus infection

Late Relapse After Hepatitis C Virus Treatment Is Rare

Few patients treated with a sofosbuvir-containing regimen for hepatitis C virus infection had late recurrent viremia, and most occurrences appeared to be reinfections.

Vemlidy (Tenofovir Alafenamide) for Treatment of Chronic Hepatitis B Virus Infection

Developed by Gilead Sciences, Vemlidy (Tenofovir Alafenamide) is indicated for the treatment of Hepatitis B virus infection with compensated liver disease in adult patients.

Researchers identify how hepatitis a virus causes liver injury

Investigators have discovered how hepatitis A virus causes liver injury as well as how the virus could jump from primates to mice. Hepatitis A virus is a vaccine preventable form of infectious hepatitis. HAV is found worldwide and is transmitted through ingestion of food and water that is contaminated with the feces of an infected person.

Janssen begins Phase IIb study of drug combination to treat hepatitis C virus infection

Janssen Research & Development has begun its Phase IIb study of combination of simeprevir, odalasvir and AL-335 to treat chronic hepatitis C virus infection without cirrhosis.

Research findings provide new avenues to target virus infection

Viral infection is one of the leading medical challenges of the 21st Century, ranging from the Hepatitis C Virus (HCV) epidemic affecting 3% of the global population, to recent outbreaks of West Nile, Zika, and Ebola viruses.

Viral hepatitis: A mouse model of hepatitis A virus infection

The 2016 Lasker Awards: Hepatitis C Virus—From Discovery to Cure

In this Viewpoint, 2016 Lasker Award winners Ralf Bartenschlager, Charles Rice, and Michael Sofia discuss their work developing a system to study the replication of hepatitis C virus and a class of antivirals to treat the infection.

NIH Grants $3 Million to Develop New Hepatitis B Treatments

Hepatitis B virus (HBV) is a viral infection that increases the likelihood of developing liver cancer or liver failure. According to the World Health Organization, an estimated 2 billion people currently are infected with HBV, which is more than 10 times the number of people who have human immunodeficiency virus (HIV). Currently, treatment for

Hepatitis C Virus Infection Becomes Reportable in New Hampshire

New Hampshire has made communicable disease reporting changes in the state, including the reporting of hepatitis C virus. State Health Alerts

[Comment] Cutting out the roots of acute hepatitis C

Hepatitis C infection is mainly a chronic liver disease with severe complications such as decompensated cirrhosis and liver cancer. Several studies have shown that the consequences of chronic hepatitis C virus (HCV) infection are not confined to the liver but also increase the risk of cardiovascular and renal diseases and cancer.1 Most patients with chronic hepatitis C were infected before 1990, w...

Hep D Virus Infection Tied to Higher Mortality in Patients With HIV/HBV Coinfection

Infection with hepatitis delta virus (HDV) in people with HIV/HBV coinfection is independently associated with higher mortality and more liver-related events, according to new findings. Reuters Health Information

UNC Researchers Identify How Hepatitis A Virus Causes Liver Injury

Hepatitis researchers have long thought that immune cells sent by the body to attack virus-infected cells in the liver cause the acute liver injury associated with hepatitis A virus (HAV) and other hepatitis viruses. Yet, investigators at the University of North Carolina at Chapel Hill have discovered that it is an immediate, intrinsic response of

Chronic Hepatitis C Virus Infection and Risk for Diabetes

Does chronic hepatitis C infection increase diabetes risk? Liver International

European Commission Grants Marketing Authorization for Gilead's Vemlidy (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection

Vemlidy is the First New Treatment for Chronic Hepatitis B Infection to be Approved in the European Union in Nearly a Decade -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Europe...

Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling

Ram Savan and colleagues report that two miRNAs known to suppress type 3 interferon (IFN) signaling also downregulate type 1IFN signaling in hepatitis C virus (HCV)-infected hepatocytes. The findings provide insights into the mechanisms by which antiviral IFN signaling is inhibited in HCV infection.

Hepatitis C Virus Genotype 4: Genotype 1's Little Brother

Treatment options for patients with chronic HCV genotype 4 infections continue to expand. What are the currently available and investigative treatments for HCV GT4 infection? Journal of Viral Hepatitis

Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand ...

"Eiger is committed to playing a leading role in developing novel treatments for HDV infection, the most severe form of hepatitis, and building awareness of Read more...

Quick Search

News Quicklinks